Annals On Call Podcast podkast

Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes

0:00
29:55
Do tyłu o 15 sekund
Do przodu o 15 sekund
Dr. Centor discusses outcomes in patients with type 2 diabetes when treated with semaglutide or dulaglutide versus empagliflozin with Drs. Kevin Kip and Anum Saeed.

Więcej odcinków z kanału "Annals On Call Podcast"